Octopus AIM VCT plc (OOA.L) is a United Kingdom-based venture capital trust that invests in a diversified portfolio of qualifying companies listed on the Alternative Investment Market (AIM) or Aquis Stock Exchange (AQSE), targeting attractive tax-free dividends and long-term capital growth for shareholders. Founded in 1997 and headquartered at 33 Holborn in London, the company, managed by Octopus Investments Limited, holds approximately 74 investments across sectors including software and computer services; pharmaceuticals and biotechnology; electronic and electrical equipment; construction and materials; investment banking and brokerage services; industrial materials; telecommunications service providers; medical equipment and services; retail; healthcare; data analytics; and identity intelligence, with notable holdings such as Sosandar, Craneware, Diaceutics and GB Group. It primarily serves experienced investors seeking exposure to established, maturing UK growth businesses, with around 80 combined holdings in Octopus AIM VCTs generating net assets of roughly £114 million as of late 2025 and a targeted 6% annual dividend yield. Recent developments include a £20 million prospectus fundraise launched in September 2024 alongside Octopus AIM VCT 2 plc, which closed fully subscribed in March 2025 after raising £12.6 million net for OOA; follow-on investments in portfolio companies such as £1.1 million in Abingdon Health plc for laboratory expansion, £0.5 million in Cambridge Cognition Holdings plc for commercial strategy execution, and £0.5 million in GENinCode plc for genomic testing; and new investments including £1.1 million in Aurrigo International plc for aviation autonomous vehicles. The trust maintains a focus on profitable, dividend-paying companies, with 67% of holdings profitable as of mid-2025, while navigating AIM market volatility through selective deal flow from IPOs and existing positions.